Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 20/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is facing a class action securities lawsuit initiated by Levi & Korsinsky, LLP, related to alleged fraud committed between June 22, 2023, and June 24, 2025. The complaint highlights significant safety risks associated with its gene therapy ELEVIDYS, including failure to detect severe side effects and the potential for halted trials due to adverse events. Investors are encouraged to assess their eligibility to participate in the lawsuit by the deadline of August 25, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta Therapeutics is facing a class action lawsuit for alleged securities fraud.
  • The lawsuit claims false statements regarding ELEVIDYS, which poses significant safety risks.
  • Claims suggest that adverse events from ELEVIDYS treatment could halt trials and impact approvals.

Full Press Release Details

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:
SRPT investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
WHAT'S NEXT? If you suffered a loss in Sarepta during the relevant time frame, you have until August 25, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 17th Floor

Tags

Frequently Asked Questions

What is the Sarepta Therapeutics class action lawsuit about?

The lawsuit addresses alleged securities fraud affecting Sarepta investors from June 22, 2023, to June 24, 2025.

What issues are raised in the securities complaint?

The complaint claims false statements regarding ELEVIDYS's safety, trial protocols, and severe side effects.

How can Sarepta investors participate in the lawsuit?

Investors have until August 25, 2025, to request lead plaintiff status without obligation.

Are there any costs to join the class action?

Class members may receive compensation without incurring any costs or fees.

Why choose Levi & Korsinsky for legal representation?

Levi & Korsinsky has a strong track record, securing substantial compensation for shareholders.

Last updated: Jul 22, 2025